- Joined
- Nov 17, 2011
- Messages
- 1,950
- Reaction score
- 905
In order to start from scratch a bit, I was reading an overview of treatment options for GAD in the Psychiatric Times. I noticed how favorable pregabalin appears. I remember doing research on medications to both help with benzo withdrawal and to help with anxiety around 2005 and finding this medication and wondering why it wasn't being used for anxiety. Ten years later and I'm still not sure why. The local treatment center near me is just now starting to use gabapentin instead of phenobarbital for benzo withdrawal, which seems like a leap made from the stone age, but I wonder why pregabalin isn't more prevalent in both inpatient rehab and outpatient use. I just read that the most commonly prescribed psychiatric drug in 2009 was Xanax. How can that be when options like pregabalin exist?
Here is the info from the Psychiatric Times:
Two similarly designed randomized, placeboand active comparator–controlled, double-blind studies evaluated the efficacy of pregabalin versus lorazepam for the treatment of GAD. The pregabalin groups and the lorazepam group all experienced greater reductions in HAM-A score by week 4 compared with placebo, with no observed statistically significant differences among the active-treatment groups. Pregabalin at its highest study dose (600 mg) produced reductions in the psychic and somatic anxiety HAM-A subscale scores that were statistically superior to those produced with placebo, whereas lorazepam produced reductions that reached statistical significance versus placebo with respect to only the somatic subscale. The improvements in HAM-A score produced by the active-treatment groups were apparent by week 1 of the study.13,14
The relative efficacy and early onset of effect of pregabalin versus commonly used benzodiazepines may represent a new therapeutic intervention for GAD as both a monotherapy (after failure of an initial monotherapy) and as an augmentation strategy. Pregabalin is renally excreted and therefore poses a low risk of drug-drug interactions, lacks withdrawal or physical dependence risk, is associated with minimal adverse effects (dizziness, weight gain, insomnia), and is safe and well tolerated. A potential role for pregabalin may be in patients who are tapering off long-term benzodiazepine monotherapy for GAD. [I said this 10 years ago and was ignored!]
- See more at: http://www.psychiatrictimes.com/spe...nxiety-disorder/page/0/4#sthash.0iXYs8B7.dpuf
Here is the info from the Psychiatric Times:
Two similarly designed randomized, placeboand active comparator–controlled, double-blind studies evaluated the efficacy of pregabalin versus lorazepam for the treatment of GAD. The pregabalin groups and the lorazepam group all experienced greater reductions in HAM-A score by week 4 compared with placebo, with no observed statistically significant differences among the active-treatment groups. Pregabalin at its highest study dose (600 mg) produced reductions in the psychic and somatic anxiety HAM-A subscale scores that were statistically superior to those produced with placebo, whereas lorazepam produced reductions that reached statistical significance versus placebo with respect to only the somatic subscale. The improvements in HAM-A score produced by the active-treatment groups were apparent by week 1 of the study.13,14
The relative efficacy and early onset of effect of pregabalin versus commonly used benzodiazepines may represent a new therapeutic intervention for GAD as both a monotherapy (after failure of an initial monotherapy) and as an augmentation strategy. Pregabalin is renally excreted and therefore poses a low risk of drug-drug interactions, lacks withdrawal or physical dependence risk, is associated with minimal adverse effects (dizziness, weight gain, insomnia), and is safe and well tolerated. A potential role for pregabalin may be in patients who are tapering off long-term benzodiazepine monotherapy for GAD. [I said this 10 years ago and was ignored!]
- See more at: http://www.psychiatrictimes.com/spe...nxiety-disorder/page/0/4#sthash.0iXYs8B7.dpuf